Tinidazole (Tindamax) For Bacterial Vaginosis
Tinidazole (Tindamax generic, Mission Phar-macal) has been approved for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the U.S.
This is the first new oral therapy to be approved for the treatment of BV in a decade. It provides a shorter course of oral therapy, with fewer doses per day and a better tolerability profile, compared with metronidazole, the current standard of care. It is the only FDA-approved therapy for both BV and trichomoniasis.
Tinidazole is administered as 1 g (two tablets) once daily for five days or 2 g (four tablets) once daily for two days; by comparison, metronidazole needs to be taken twice daily for seven days. Unlike intravaginal treatments, tinidazole treats the entire reproductive tract.
The approval for BV was based on a randomized, placebo-controlled, double-blind multicenter trial evaluating two dosing regimens of the drug.
In the U.S., tinidazole been approved for use since May 2004 and is indicated for patients with bacterial vaginosis, trichomoniasis, giardiasis and intestinal amebiasis, and amebic liver abscess.
